Two-year outcomes of intravitreal ranibizumab for myopic choroidal neovascularization

Kumiko Suehiro, Sacomi Shiose, Kumiko Kano, Sawako Hashimoto, Iori Wada, Yuji Oshima, Koh Hei Sonoda

Research output: Contribution to journalArticle

Abstract

Purpose : To report the 2-year outcomes of intravitreal ranibizumab (IVR) for myopic choroidal neovascularization (mCNV). Cases and Methods ' Twenty-one patients with treatment-naive mCNV who visited Kyushu University Hospital from September 2013 to August 2016 underwent IVR and were followed up for 24 months or longer. Visual acuity, central retinal thickness (CRT), retinal thickness at CNV, thickness of CNV and the area of the CNV-related macular atrophy were retrospectively compared before and after IVR. CRT, retinal thickness at CNV, and thickness of CNV were evaluated with optical coherence tomography (OCT) and the area of macular atrophy was evaluated with fundus photographs. Results ! The mean age of the subjects was 68.9 years and the mean number of IVR was 5.7. Mean visual acuity significantly improved from 1 month after to 24 months after compared with baseline values (l, 3, 6, 12 months p<0.01, 18, 24 months p<0.05), but decreased gradually from 12 months. Mean CRT, retinal thickness at CNV, and thickness of CNV significantly improved at all points (p< 0.01). Mean area of macular atrophy became significantly enlarged 6 months after (p<0.0l) and expanded gradually during the observation period. Visual acuity after 2 years was correlated with visual acuity before treatment and the area of macular atrophy after 2 years. The amount of change in the macular atrophy area after 2 years was correlated with the number of IVR. Conclusion ; IVR resulted in improvement of retinal shape and regression of the CNV, but enlargement of macular atrophy was noted in the long term. There was a tendency that the area of macular atrophy became enlarged in patients who received frequent administration.

Original languageEnglish
Pages (from-to)871-877
Number of pages7
JournalJapanese Journal of Clinical Ophthalmology
Volume73
Issue number7
Publication statusPublished - Jul 2019

Fingerprint

Choroidal Neovascularization
Atrophy
Visual Acuity
Optical Coherence Tomography
Ranibizumab
Observation
Therapeutics

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Two-year outcomes of intravitreal ranibizumab for myopic choroidal neovascularization. / Suehiro, Kumiko; Shiose, Sacomi; Kano, Kumiko; Hashimoto, Sawako; Wada, Iori; Oshima, Yuji; Sonoda, Koh Hei.

In: Japanese Journal of Clinical Ophthalmology, Vol. 73, No. 7, 07.2019, p. 871-877.

Research output: Contribution to journalArticle

Suehiro, Kumiko ; Shiose, Sacomi ; Kano, Kumiko ; Hashimoto, Sawako ; Wada, Iori ; Oshima, Yuji ; Sonoda, Koh Hei. / Two-year outcomes of intravitreal ranibizumab for myopic choroidal neovascularization. In: Japanese Journal of Clinical Ophthalmology. 2019 ; Vol. 73, No. 7. pp. 871-877.
@article{e1ab704c882c49449af5573d5bc58e86,
title = "Two-year outcomes of intravitreal ranibizumab for myopic choroidal neovascularization",
abstract = "Purpose : To report the 2-year outcomes of intravitreal ranibizumab (IVR) for myopic choroidal neovascularization (mCNV). Cases and Methods ' Twenty-one patients with treatment-naive mCNV who visited Kyushu University Hospital from September 2013 to August 2016 underwent IVR and were followed up for 24 months or longer. Visual acuity, central retinal thickness (CRT), retinal thickness at CNV, thickness of CNV and the area of the CNV-related macular atrophy were retrospectively compared before and after IVR. CRT, retinal thickness at CNV, and thickness of CNV were evaluated with optical coherence tomography (OCT) and the area of macular atrophy was evaluated with fundus photographs. Results ! The mean age of the subjects was 68.9 years and the mean number of IVR was 5.7. Mean visual acuity significantly improved from 1 month after to 24 months after compared with baseline values (l, 3, 6, 12 months p<0.01, 18, 24 months p<0.05), but decreased gradually from 12 months. Mean CRT, retinal thickness at CNV, and thickness of CNV significantly improved at all points (p< 0.01). Mean area of macular atrophy became significantly enlarged 6 months after (p<0.0l) and expanded gradually during the observation period. Visual acuity after 2 years was correlated with visual acuity before treatment and the area of macular atrophy after 2 years. The amount of change in the macular atrophy area after 2 years was correlated with the number of IVR. Conclusion ; IVR resulted in improvement of retinal shape and regression of the CNV, but enlargement of macular atrophy was noted in the long term. There was a tendency that the area of macular atrophy became enlarged in patients who received frequent administration.",
author = "Kumiko Suehiro and Sacomi Shiose and Kumiko Kano and Sawako Hashimoto and Iori Wada and Yuji Oshima and Sonoda, {Koh Hei}",
year = "2019",
month = "7",
language = "English",
volume = "73",
pages = "871--877",
journal = "Japanese Journal of Clinical Ophthalmology",
issn = "0370-5579",
publisher = "Igaku-Shoin Ltd",
number = "7",

}

TY - JOUR

T1 - Two-year outcomes of intravitreal ranibizumab for myopic choroidal neovascularization

AU - Suehiro, Kumiko

AU - Shiose, Sacomi

AU - Kano, Kumiko

AU - Hashimoto, Sawako

AU - Wada, Iori

AU - Oshima, Yuji

AU - Sonoda, Koh Hei

PY - 2019/7

Y1 - 2019/7

N2 - Purpose : To report the 2-year outcomes of intravitreal ranibizumab (IVR) for myopic choroidal neovascularization (mCNV). Cases and Methods ' Twenty-one patients with treatment-naive mCNV who visited Kyushu University Hospital from September 2013 to August 2016 underwent IVR and were followed up for 24 months or longer. Visual acuity, central retinal thickness (CRT), retinal thickness at CNV, thickness of CNV and the area of the CNV-related macular atrophy were retrospectively compared before and after IVR. CRT, retinal thickness at CNV, and thickness of CNV were evaluated with optical coherence tomography (OCT) and the area of macular atrophy was evaluated with fundus photographs. Results ! The mean age of the subjects was 68.9 years and the mean number of IVR was 5.7. Mean visual acuity significantly improved from 1 month after to 24 months after compared with baseline values (l, 3, 6, 12 months p<0.01, 18, 24 months p<0.05), but decreased gradually from 12 months. Mean CRT, retinal thickness at CNV, and thickness of CNV significantly improved at all points (p< 0.01). Mean area of macular atrophy became significantly enlarged 6 months after (p<0.0l) and expanded gradually during the observation period. Visual acuity after 2 years was correlated with visual acuity before treatment and the area of macular atrophy after 2 years. The amount of change in the macular atrophy area after 2 years was correlated with the number of IVR. Conclusion ; IVR resulted in improvement of retinal shape and regression of the CNV, but enlargement of macular atrophy was noted in the long term. There was a tendency that the area of macular atrophy became enlarged in patients who received frequent administration.

AB - Purpose : To report the 2-year outcomes of intravitreal ranibizumab (IVR) for myopic choroidal neovascularization (mCNV). Cases and Methods ' Twenty-one patients with treatment-naive mCNV who visited Kyushu University Hospital from September 2013 to August 2016 underwent IVR and were followed up for 24 months or longer. Visual acuity, central retinal thickness (CRT), retinal thickness at CNV, thickness of CNV and the area of the CNV-related macular atrophy were retrospectively compared before and after IVR. CRT, retinal thickness at CNV, and thickness of CNV were evaluated with optical coherence tomography (OCT) and the area of macular atrophy was evaluated with fundus photographs. Results ! The mean age of the subjects was 68.9 years and the mean number of IVR was 5.7. Mean visual acuity significantly improved from 1 month after to 24 months after compared with baseline values (l, 3, 6, 12 months p<0.01, 18, 24 months p<0.05), but decreased gradually from 12 months. Mean CRT, retinal thickness at CNV, and thickness of CNV significantly improved at all points (p< 0.01). Mean area of macular atrophy became significantly enlarged 6 months after (p<0.0l) and expanded gradually during the observation period. Visual acuity after 2 years was correlated with visual acuity before treatment and the area of macular atrophy after 2 years. The amount of change in the macular atrophy area after 2 years was correlated with the number of IVR. Conclusion ; IVR resulted in improvement of retinal shape and regression of the CNV, but enlargement of macular atrophy was noted in the long term. There was a tendency that the area of macular atrophy became enlarged in patients who received frequent administration.

UR - http://www.scopus.com/inward/record.url?scp=85070991715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070991715&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85070991715

VL - 73

SP - 871

EP - 877

JO - Japanese Journal of Clinical Ophthalmology

JF - Japanese Journal of Clinical Ophthalmology

SN - 0370-5579

IS - 7

ER -